{
  "id": 15545231,
  "title": "Samsung Biologics Highlights ADC Manufacturing Strength",
  "url": "https://urgent.news/2026/10/19/samsung-biologics-highlights-adc-manufacturing-strength",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-19T02:56:32.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=279093"
  },
  "original_language": "en",
  "account": null,
  "summary": "Samsung Biologics has emphasized its manufacturing capabilities in the field of ADCs (Antibody Drug Conjugates) at the World ADC San Diego 2026 event, taking place from October 12 to 15 in San Diego, California. The company has been operating a full ADC process at a single site in Songdo, Incheon since launching its dedicated ADC production facility in March 2025. Samsung Biologics aims to further bolster its end-to-end service system by establishing and commencing operations of a dedicated ADC drug product (DP) line by 2027. The company highlighted its strengths in Contract Research Organization (CRO), Contract Development Organization (CDO), and Contract Manufacturing Organization (CMO) services, showcasing its ability to handle the entire ADC manufacturing process. Additionally, Samsung Biologics is planning to expand its biopharmaceutical conjugation services and is set to introduce new modalities such as peptides to further solidify its response capabilities to diverse customer needs.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}